Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation.
In vitro metabolism of methadone was investigated in cytochrome P450 (CYP) supersomes and phenotyped human liver microsomes (HLMs) to reconcile past findings on CYP involvement in stereo-selective metabolism of methadone. Racaemic methadone was used for incubations; (R)- and (S)-methadone turnover and (R)- and (S)-EDDP formation were determined using chiral liquid chromatography-tandem mass spectrometry. CYP supersome activity for methadone use and EDDP formation ranked CYP2B6 > 3A4 > 2C19 > 2D6 > 2C18, 3A7 > 2C8, 2C9, 3A5. After abundance scaling, CYP3A4, 2B6 and 2C19 accounted for 63-74, 12-32 and 1. 4-14% of respective activity. CYP2B6, 2D6 and 2C18 demonstrated a preference for (S)-EDDP formation; CYP2C19, 3A7 and 2C8 for (R)-EDDP; 3A4 none. Correlation analysis with 15 HLMs supported the involvement of CYP2B6 and 3A. The significant correlation of S/R ratio with CYP2B6 activity confirmed its stereo-selectivity. CYP2C19 and 2D6 inhibitors and monoclonal antibody (mAb) did not inhibit EDDP formation in HLM. Chemical and mAb inhibition of CYP3A in high 3A activity HLM reduced EDDP formation by 60-85%; inhibition of CYP2B6 in 2B6 high-activity HLM reduced (S)-EDDP formation by 80% and (R)-EDDP formation by 55%. Inhibition changed methadone metabolism in a stereo-selective manner. When CYP3A was inhibited, 2B6 mediated (S)-EDDP formation predominated; S/R stereo-selectivity increased. When 2B6 was inhibited (S)-EDDP formation fell and stereo-selectivity decreased. The results confirmed the primary roles of CYPs 3A4 and 2B6 in methadone metabolism; CYP2C8 and 2C9 did not appear involved; 2C19 and 2D6 have minimal roles. CYP2B6 is the primary determinant of stereo-selective metabolism; stereo-selective inhibition might play a role in varied plasma concentrations of the two enantiomers.
Chang
Yan
Y
Center for Human Toxicology, Department of Pharmacology and Toxicology, University of Utah, 417 Wakara Way, Salt Lake City, UT, USA.
Fang
Wenfang B
WB
Lin
Shen-Nan
SN
Moody
David E
DE
D000701:Analgesics, Opioid / Q000737:chemistry / Q000378:metabolism* / Q000633:toxicity; D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors / Q000378:metabolism; D065702:Cytochrome P-450 CYP2B6; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D065692:Cytochrome P-450 CYP3A Inhibitors; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D006801:Humans; D008691:Methadone / Q000737:chemistry / Q000378:metabolism* / Q000633:toxicity; D008862:Microsomes, Liver / Q000201:enzymology / Q000378:metabolism*; D010089:Oxidoreductases, N-Demethylating / Q000037:antagonists & inhibitors / Q000378:metabolism; D013237:Stereoisomerism
D000701:Analgesics, Opioid; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D065692:Cytochrome P-450 CYP3A Inhibitors; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System; D001189:Aryl Hydrocarbon Hydroxylases; C585599:CYP2B6 protein, human; C045793:CYP2C19 protein, human; D065702:Cytochrome P-450 CYP2B6; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D010089:Oxidoreductases, N-Demethylating; D008691:Methadone
J Pharmacol Exp Ther. 2007 Apr;321(1):389-99
17259447
Electrophoresis. 2003 Aug;24(15):2577-87
12900870
Clin Pharmacol Ther. 2008 Oct;84(4):497-505
19238655
Drug Metab Dispos. 1997 Dec;25(12):1347-53
9394023
Chirality. 2004 Jan;16(1):36-44
14628297
Biochem Biophys Res Commun. 2001 Jun 15;284(3):751-6
11396966
Drug Metab Dispos. 2000 Dec;28(12):1493-504
11095589
Clin Pharmacol Ther. 2004 Sep;76(3):250-69
15371986
Br J Clin Pharmacol. 2000 Nov;50(5):427-40
11069437
Anesthesiology. 2009 Mar;110(3):660-72
19225389
Br J Clin Pharmacol. 1999 Apr;47(4):403-12
10233205
Ann N Y Acad Sci. 1976;281:350-71
798526
Pharmacogenetics. 1997 Jun;7(3):165-79
9241656
J Clin Psychopharmacol. 2001 Apr;21(2):229-34
11270921
Drug Metab Dispos. 2003 Jun;31(6):742-7
12756206
Anesthesiology. 2008 Mar;108(3):363-74
18292673
Drug Metab Dispos. 2007 Oct;35(10):1853-9
17639026
J Pharmacol Exp Ther. 1948 Jul;93(3):282-6
18882133
J Anal Toxicol. 2008 Apr;32(3):208-19
18397572
Br J Clin Pharmacol. 2000 Apr;49(4):343-51
10759690
Drug Metab Dispos. 1999 Jan;27(1):102-9
9884317
Chem Res Toxicol. 1996 Mar;9(2):365-73
8839037
Clin Pharmacol Ther. 2005 Dec;78(6):593-604
16338275
Clin Pharmacol Ther. 2007 May;81(5):719-28
17329992
Life Sci. 1995;56(2):PL45-50
7823756
Drug Metab Dispos. 2007 Nov;35(11):2053-9
17682072
J Pharmacol Exp Ther. 2004 Jan;308(1):189-97
14563790
Clin Pharmacol Ther. 2006 Dec;80(6):668-81
17178267
Ther Drug Monit. 1996 Jun;18(3):221-7
8738759
Clin Pharmacokinet. 2002;41(14):1153-93
12405865
Am J Addict. 2010 Jan-Feb;19(1):4-16
20132117
Drug Metab Dispos. 2004 Jun;32(6):626-31
15155554
Br J Clin Pharmacol. 2009 Jan;67(1):29-37
19133059
Drug Metab Dispos. 1997 Mar;25(3):390-3
9172960
Pharmacol Res. 2004 Dec;50(6):551-9
15501692